To interrupt M-CSF signaling we selected sunitinib, a small-molecule receptor tyrosine kinase inhibitor that is US FDA approved for pancreatic cancer, gastrointestinal stromal tumors, and renal cell carcinoma. This evidence concerns the gene NTRK1 and familial pancreatic carcinoma.